| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
FT827 targets ubiquitin-specific protease 7 (USP7). USP7 is a deubiquitinating enzyme that regulates the stability of various proteins. FT827 is a covalent inhibitor that forms an irreversible bond with the catalytic cysteine residue (Cys223) in the active site of USP7. This covalent binding leads to sustained inhibition of USP7 activity.
|
|---|---|
| ln Vitro |
In vitro, FT827 is a selective and covalent USP7 inhibitor. It has a Ki of 4.2 μM and a Kd of 7.8 μM for the USP7 catalytic domain. Its covalent binding mechanism has been characterized. It is a potent inhibitor of USP7 activity.
|
| ln Vivo |
In vivo, FT827 has been studied for its anticancer activity. By inhibiting USP7, it destabilizes its substrates, leading to the accumulation of tumor suppressor proteins and inhibition of tumor growth. Its efficacy is being evaluated in preclinical models.
|
| Enzyme Assay |
In vitro enzyme assays for FT827 measure its inhibition of USP7 activity. The compound is incubated with USP7 and a fluorogenic ubiquitin substrate. Its covalent binding is confirmed by mass spectrometry or other methods. The Ki and Kd values are determined.
|
| Cell Assay |
In vitro cell-based assays for FT827 involve treating cancer cells with the compound and measuring its effects on cell viability and USP7 activity. Its effects on USP7 substrates are assessed by Western blotting. Its covalent binding to USP7 in cells can be demonstrated by pull-down assays.
|
| Animal Protocol |
In vivo animal experiments for FT827 have been conducted in tumor xenograft models. Tumor-bearing mice are treated with FT827, and tumor growth inhibition is monitored. Its effects on USP7 activity and its substrates in tumor tissues are assessed.
|
| ADME/Pharmacokinetics |
FT827 has a molecular weight of 548.61 and a molecular formula of C27H28N6O5S. Its purity is typically high. It is soluble in DMSO. It is typically stored under recommended conditions for research compounds.
|
| Toxicity/Toxicokinetics |
FT827 is for research use only and is not intended for human use. Its safety profile is being evaluated in preclinical studies. As a covalent USP7 inhibitor, its toxicity is related to its mechanism of action. Standard safety precautions should be taken when handling.
|
| Additional Infomation |
FT827 is a selective and covalent USP7 inhibitor. It has a Ki of 4.2 μM and a Kd of 7.8 μM. It features a vinylsulfonamide warhead that covalently binds to Cys223 of USP7. It is being investigated for its anticancer activity.
|
| Molecular Formula |
C27H28N6O5S
|
|---|---|
| Molecular Weight |
548.613424301147
|
| Exact Mass |
548.184
|
| CAS # |
1959537-86-0
|
| PubChem CID |
121435663
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.5
|
| tPSA |
146
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
39
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C2=C(C=N1)C(=O)N(C=N2)CC3(CCN(CC3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5NS(=O)(=O)C=C)O
|
| InChi Key |
GFNJQQBUZURQMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H28N6O5S/c1-3-39(37,38)30-23-7-5-4-6-21(23)19-8-10-20(11-9-19)25(34)32-14-12-27(36,13-15-32)17-33-18-28-24-22(26(33)35)16-29-31(24)2/h3-11,16,18,30,36H,1,12-15,17H2,2H3
|
| Chemical Name |
N-[2-[4-[4-hydroxy-4-[(1-methyl-4-oxopyrazolo[3,4-d]pyrimidin-5-yl)methyl]piperidine-1-carbonyl]phenyl]phenyl]ethenesulfonamide
|
| Synonyms |
FT-827 FT 827 FT827
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8228 mL | 9.1139 mL | 18.2279 mL | |
| 5 mM | 0.3646 mL | 1.8228 mL | 3.6456 mL | |
| 10 mM | 0.1823 mL | 0.9114 mL | 1.8228 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.